(2S,6R)-1-benzyl-2,6-dimethylpiperazine | 59794-53-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2S,6R)-1-benzyl-2,6-dimethylpiperazine
• 英文别名: 1-benzyl-2,6-dimethyl-piperazine；1-Benzyl-cis-2,6-dimethyl-piperazin；cis-1-Benzyl-2,6-dimethylpiperazine
• CAS: 59794-53-5
• 化学式: C₁₃H₂₀N₂
• 分子量: 204.315
• InChiKey: BNPHYNQCHNBJEL-TXEJJXNPSA-N

物化性质

• 沸点：
  91-92 °C(Press: 0.2 Torr)
• 密度：
  0.964±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2S,6R)-1-benzyl-2,6-dimethylpiperazine 在 盐酸 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 乙腈 为溶剂， 反应 32.0h， 生成 methyl 6-(((3R,5S)-4-benzyl-3,5-dimethylpiperazin-1-yl)methyl)-1H-indole-2-carboxylate hydrochloride salt
  参考文献：
  名称：

  [EN] NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
  [FR] NOUVEAUX COMPOSÉS EN TANT QU'INHIBITEURS DE L'HISTONE DÉSACÉTYLASE 6 ET COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT

  摘要：

  本发明涉及具有组蛋白去乙酰化酶6（HDAC6）抑制活性的新化合物，其异构体或其药用盐，其用于制备治疗药物的用途，包括相同的药物组成部分的药物组合物，使用该组合物治疗疾病的方法，以及制备新化合物的方法。根据本发明的新化合物具有组蛋白去乙酰化酶6（HDAC6）抑制活性，并且对于预防或治疗HDAC6相关疾病（包括癌症、炎症性疾病、自身免疫疾病、神经系统疾病和神经退行性疾病）有效。

  公开号：

  WO2015137750A1
• 作为产物：
  描述：

  1-Benzyl-4-benzoyl-cis-2,6-dimethyl-piperazin 、 sodium hydroxide 以86%的产率得到
  参考文献：
  名称：

  SAAVEDRA J. E.; LYLE G. G.; LYLE R. E., ORG. PREP. AND PROCED. INT., 1976, 8, NO 1-2, 19-23

  摘要：

  DOI：

文献信息

• Piperazine derivatives, their preparation and uses in therapy (5ht1b receptor activity)
  申请人：——

  公开号：US20040132720A1

  公开（公告）日：2004-07-08

  Compounds of formula (I) or a pharmaceutically acceptable salt thereof are disclosed: in which R a is a group of formula (i) wherein P 1 is phenyl, naphthyl or heteroaryl; R 1 is halogen, C 1-6 alkyl, C 3-6 cycloalkyl, COC 1-6 alkyl, C 1-6 alkoxy, hydroxy, hydroxyC 1-6 alkyl, nitro, haloC 1-6 alkyl, cyano, SR 6 , SOR 6 , SO 2 R 6 , SO 2 NR 6 R 7 , CO 2 R 6 , CONR 6 R 7 , OCONR 6 COR 7 , NR 6 r 7 , NR 6 COR 7 , NR 6 CO 2 R 7 , NR 6 SO 2 R 7 , NR 6 CONR 7 R 8 , CH 2 NR 6 COR 7 , CH 2 NR 6 CO 2 R 7 , CH 2 NR 6 SO 2 R 7 , CR 6 ═NOR 7 where R 6 , R 7 and R 8 are independently hydrogen or C 1-6 alkyl, a is 1, 1, 2, or 3; or R a is a group of formula (ii) where P 2 is phenyl, naphthyl, heteroaryl or a 5 to 7 membered heterocyclic ring; P 3 is phenyl, naphthyl or heteroaryl; R 2 is a defined above for R 1 in formula (I) or R 2 is heteroaryl optionally substituted By C 1 alkyl, halogen or COC 1-6 alkyl or is a 5-7 membered heterocyclic ring optionally substituted by oxo; R 3 is halogen, C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 alkyl, COC 1-6 alkyl, hydroxy, intro, haloC 1-6 alkyl, cyano, CO 2 R 6 , CONR 6 R 7 , NR 6 R 7 where R 6 and R 7 are as defined above; b and c are independently 0, 1, 2, or 3; Y is a single bond, CH 2 or NH; X is oxygen, sulfur or N—R 5 where R 5 is hydrogen or C 1-6 alkyl; R b is hydrogen, halogen, C 1-6 alkyl, haloC 1-6 alkyl, COC 1-6 alkyl or cyano; R c is hydrogen or C 1-6 alkyl. Processes for their preparation, pharmaceutical compositions containing them and their use in therapy as 5-HT 1B receptor antagonists, for diseases such as depression, are also disclosed. 1

  公开了化学式（I）或其药学上可接受的盐的化合物：其中，R是式（i）的基团，其中P1是苯基、萘基或杂环基；R1是卤素、C1-6烷基、C3-6环烷基、COC1-6烷基、C1-6烷氧基、羟基、羟基C1-6烷基、硝基、卤C1-6烷基、氰基、SR6、SOR6、SO2R6、SO2NR6R7、CO2R6、CONR6R7、OCONR6COR7、NR6r7、NR6COR7、NR6CO2R7、NR6SO2R7、NR6CONR7R8、CH2NR6COR7、CH2NR6CO2R7、CH2NR6SO2R7、CR6═NOR7，其中R6、R7和R8独立地为氢或C1-6烷基，a为1、1、2或3；或R是式（ii）的基团，其中P2是苯基、萘基、杂环基或5-7成员的杂环环；P3是苯基、萘基或杂环基；R2是在式（I）中定义的R1或R2是杂环基，可选地被C1烷基、卤素或COC1-6烷基取代，或是5-7成员的杂环环，可选地被氧代取代；R3是卤素、C1-6烷基、C3-6环烷基、C1-6烷氧基、羟基、介绍、卤C1-6烷基、氰基、CO2R6、CONR6R7、NR6R7，其中R6和R7如上所述；b和c独立地为0、1、2或3；Y是单键、CH2或NH；X是氧、硫或N-R5，其中R5是氢或C1-6烷基；Rb是氢、卤素、C1-6烷基、卤C1-6烷基、COC1-6烷基或氰基；Rc是氢或C1-6烷基。还公开了其制备方法、含有它们的药物组合物以及它们在治疗抑郁等疾病中作为5-HT1B受体拮抗剂的用途。
• Piperazine derivatives as 5-HT1B antagonists
  申请人：SmithKline Beecham p.I.c.

  公开号：US20040176388A1

  公开（公告）日：2004-09-09

  Piperazine derivatives of formula (I) processes for their preparation, pharmaceutical compositions containing them and to their use in therapy as 5-HT 1B antagonists. W,Y,R a -R e are so defined in the application. 1

  公式(I)的吡哆醇衍生物，其制备方法，包含它们的制药组合物以及它们作为5-HT1B拮抗剂在治疗中的应用。其中，W，Y，Ra-Re在申请中有定义。
• PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE
  申请人：Castelhano Arlindo

  公开号：US20080261943A1

  公开（公告）日：2008-10-23

  The subject invention provides compounds having the structure: wherein, R 1 is a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NR a R b , —NR a R b , —NR a C(═O)NR a R b , —NR a C(═O)OR a , —OC(═O)NR a R b , or —NH C(═O) R a ; R 2 is hydrogen or a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NR a R b , —NR a R b , —NR a C(═O)NR a R b , —NR a C(═O)OR a , —OC(═O)NR a R b , or —NHC(═O)R a , or R 1 , R 2 and N together form a substituted piperazine, substituted azetidine ring, or a pyrrolidine ring substituted with —(CH 2 ) 2 OH or —CH 2 C(═O)OH; R 3 is a substituted or unsubstituted phenyl or a 5-6 membered heteroaryl ring, wherein the substituent is halogen, hydroxyl, cyano, (C 1 -C 15 )alkyl, (C 1 -C 15 )alkoxy, or —NR a R b ; R 4 is hydrogen or substituted or unsubstituted (C 1 -C 15 )alkyl; R 5 is —(CH 2 ) m OR 6 , —CHNOR 7 , —C(═O)NR 8 R 9 , —(CH 2 ) m C(═O)OR 10 , —(CH 2 ) k C(═O)NR 11 R 12 ; wherein R 6 is a substituted or unsubstituted (C 1 -C 30 )alkyl, (C 3 -C 10 )cycloalkyl, or an aryl, heteroaryl or 4-8 membered heterocyclic ring; R 7 is hydrogen, or a substituted or unsubstituted (C 1 -C 30 )alkyl, (C 1 -C 30 )alkylaryl; R 8 and R 9 are each independently hydrogen, or a substituted or unsubstituted (C 1 -C 30 )alkyl, (C 1 -C 30 )alkylaryl, (C 1 -C 30 )alkylamino, (C 1 -C 30 )alkoxy, or a saturated or unsaturated, monocyclic or bicyclic, carbocyclic or heterocyclic ring, or R 8 , N, and R 9 together form a substituted or unsubstituted 4-8 membered heterocyclic ring; R 10 is hydrogen or a substituted or unsubstituted (C 1 -C 30 )alkyl, (C 3 -C 10 )cycloalkyl, or an aryl, heteroaryl or heterocyclic ring; R 11 , N and R 12 together form a 4-8 membered heterocyclic ring; R a and R b are each independently hydrogen or alkyl; m is 0, 1, 2 or 3; and k is 1, 2 or 3, or a specific enantiomer thereof, or a specific tautomer thereof, or a pharmaceutically acceptable salt thereof, and a method for treating a disease associated with the A 2b adenosine receptor in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of the compounds of the invention.

  本发明提供了具有以下结构的化合物：其中，R1是取代或未取代的烷基，其中取代基是羟基，二羟基，羧基，—C（═O）NRaRb，—NRaRb，—NRaC（═O）NRaRb，—NRaC（═O）ORa，—OC（═O）NRaRb或—NH C（═O） Ra；R2是氢或取代或未取代的烷基，其中取代基是羟基，二羟基，羧基，—C（═O）NRaRb，—NRaRb，—NRaC（═O）NRaRb，—NRaC（═O）ORa，—OC（═O）NRaRb或—NHC（═O）Ra，或R1，R2和N共同形成取代的哌嗪，取代的氮杂环丙烷环或取代的吡咯烷环，取代基为—（CH2）2OH或—CH2C（═O）OH；R3是取代或未取代的苯基或5-6成员的杂芳基环，其中取代基为卤素，羟基，氰基，（C1-C15）烷基，（C1-C15）烷氧基或—NRaRb；R4是氢或取代或未取代的（C1-C15）烷基；R5是—（CH2）mOR6，—CHNOR7，—C（═O）NR8R9，—（CH2）mC（═O）OR10，—（CH2）kC（═O）NR11R12；其中，R6是取代或未取代的（C1-C30）烷基，（C3-C10）环烷基或芳基，杂芳基或4-8成员的杂环；R7是氢或取代或未取代的（C1-C30）烷基，（C1-C30）烷基芳基；R8和R9各自独立地是氢或取代或未取代的（C1-C30）烷基，（C1-C30）烷基芳基，（C1-C30）烷基氨基，（C1-C30）烷氧基或饱和或不饱和的单环或双环，碳环或杂环，或R8，N和R9共同形成取代或未取代的4-8成员的杂环；R10是氢或取代或未取代的（C1-C30）烷基，（C3-C10）环烷基，芳基，杂芳基或杂环；R11，N和R12共同形成4-8成员的杂环；Ra和Rb各自独立地是氢或烷基；m为0，1，2或3；k为1，2或3，或其特定对映体，或其特定互变异构体，或其药学上可接受的盐，以及一种用于治疗与A2b腺苷受体相关的疾病的方法，包括向需要这种治疗的受体中施用本发明化合物的治疗有效量。
• Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
  申请人：Anderson Eric

  公开号：US20080004312A1

  公开（公告）日：2008-01-03

  The present invention relates to urotensin II receptor antagonists, pharmaceutical compositions containing them and their use.

  本发明涉及尿加压素II受体拮抗剂、含有它们的制药组合物以及它们的使用。
• SILYLALKYLOXYARYL COMPOUNDS AND METHODS FOR TREATING CANCER
  申请人：THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE

  公开号：US20160159832A1

  公开（公告）日：2016-06-09

  Silylalkyloxyaryl compounds useful as anti-cancer agents. The compounds and pharmaceutical compositions containing them are particularly useful for the treatment of melanoma, colon, neuroblastoma, bladder, breast, lung, pancreatic, melanoma, sarcoma, lymphoma or gastric cancer.

  Silylalkyloxyaryl化合物可用作抗癌剂。这些化合物和含有它们的制药组合物特别适用于黑色素瘤、结肠癌、神经母细胞瘤、膀胱癌、乳腺癌、肺癌、胰腺癌、黑色素瘤、肉瘤、淋巴瘤或胃癌的治疗。